Investment
Features
FeesSafety
Academy
More
Pluang+

X-Ray-activated Rutherrin® shows 100% complete response in preclinical bladder cancer study

Market News
13 Apr 2026
Newsfile Corp
View Source
Bullish
pluang ai news

Theralase Technologies announced that X-Ray-activated Rutherrin® achieved a 100% complete response rate in animals with Muscle Invasive Bladder Cancer (MIBC) in a preclinical study, with all treated animals remaining cancer-free. This treatment outperformed radiation-only and untreated groups, which showed lower survival rates. The results support Rutherrin®'s potential as a bladder-sparing cancer therapy and pave the way for planned clinical trials in 2026. This advancement could improve treatment outcomes and quality of life for MIBC patients, a group with significant unmet medical needs.

More News (TLT)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App